Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906655 · ClinicalTrials.gov registry record · Phase 2
An Open Label Study for Palmar Hyperhydrosis
A Phase 2 study of Skin Diseases and Hyperhidrosis, sponsored by Pariser, Robert J., M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT04906655: Completed Phase 2 study of Skin Diseases and Hyperhidrosis, sponsored by Pariser, Robert J., M.D..
NCT04906655 is a Phase 2 study of Skin Diseases and Hyperhidrosis that has completed, run by Pariser, Robert J., M.D.. The registered enrollment target is 120 participants, below the 201-participant average among 14 other Skin Diseases trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04906655, a Phase 2 study of Skin Diseases and Hyperhidrosis, has completed, sponsored by Pariser, Robert J., M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this open-label study is to evaluate the efficacy and safety of different methods of application of glycopyrronium cloth, 2.4% in patients with palmar hyperhidrosis
Primary Outcome
The hand sweat severity (HSS) item is a patient reported outcome, collected nightly, and is designed to measure the severity of palmar hyperhidrosis.
Conditions Studied
Interventions
- DRUG Glycopyrronium 2.4 % Medicated Cloth
Study Locations (1)
Virginia
- Virginia Clinical Research, Inc. - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2021-05-20 |
| Phase | Phase 2 |
What the finished NCT04906655 record still lists
NCT04906655 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 201-participant average among 14 other Skin Diseases trials with a reported enrollment target (40% lower).
The record links to 4 conditions, with Skin Diseases appearing as the primary indexed condition, and to 1 intervention - of which Glycopyrronium 2.4 % Medicated Cloth is the first listed.
NCT04906655 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04906655 about?
NCT04906655 is a clinical study titled "An Open Label Study for Palmar Hyperhydrosis". The purpose of this open-label study is to evaluate the efficacy and safety of different methods of application of glycopyrronium cloth, 2.4% in patients with palmar hyperhidrosis
What is the current status of trial NCT04906655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2020-10-01. Estimated completion is 2021-05-20.
What conditions does trial NCT04906655 study?
This clinical trial studies the following conditions: Skin Diseases, Hyperhidrosis, Palmar Hyperhidrosis, Sweat Gland Diseases.
What interventions are being tested in trial NCT04906655?
The interventions under investigation include: Glycopyrronium 2.4 % Medicated Cloth (DRUG).
Who is sponsoring clinical trial NCT04906655?
This trial is sponsored by Pariser, Robert J., M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906655 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04906655's enrollment target sits among peer trials
120 7th of 14 higher than 8 of 14 other Skin Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI